| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 352 | 436 | 440 | 452 |
| Cost of Material Consumed | 246 | 342 | 326 | 332 |
| Change in Inventory | 2 | -28 | -15 | 2 |
| Gross Margins | 29.55 | 27.98 | 29.32 | 26.11 |
| Employee Benefit Expenses | 51 | 56 | 63 | 55 |
| Other Expenses | 42 | 41 | 42 | 45 |
| EBITDA | 11 | 25 | 24 | 18 |
| OPM | 3.13 | 5.73 | 5.45 | 3.98 |
| Other Income | 11 | 10 | 7 | 11 |
| Finance Cost | 0 | 0.6 | 0.3 | 0.3 |
| D&A | 12 | 11 | 7 | 4.6 |
| EBIT | -1 | 14 | 17 | 13.4 |
| EBIT Margins | -0.28 | 3.21 | 3.86 | 2.96 |
| PBT | 10 | 22 | 24 | 23 |
| PBT Margins | 2.84 | 5.05 | 5.45 | 5.09 |
| Tax | 3 | 9 | 6 | 5 |
| PAT | 7 | 13 | 18 | 18 |
| NPM | 1.99 | 2.98 | 4.09 | 3.98 |
| EPS | 1.56 | 2.9 | 4.02 | 4.02 |
Financial Ratios |
2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 3.13 | 5.73 | 5.45 | 3.98 |
| Net Profit Margin | 1.99 | 2.98 | 4.09 | 3.98 |
| Earning Per Share (Diluted) | 1.56 | 2.9 | 4.02 | 4.02 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 17 | 11.6 | 11 | 7.5 |
| CWIP | 0.7 | 2.4 | 0.23 | 0.1 |
| Investments | 0 | 0 | 0.03 | 0.03 |
| Trade Receivables | 42 | 51 | 39 | 53 |
| Inventory | 50 | 78 | 98 | 94.5 |
| Other Assets | 281.3 | 249 | 288.74 | 275.87 |
| Total Assets | 391 | 392 | 437 | 431 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 44.8 | 44.8 | 44.8 | 44.8 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 175 | 185 | 204 | 222 |
| Borrowings | 0 | 0 | 0 | 0 |
| Trade Payables | 80 | 68 | 87 | 73 |
| Other Liabilities | 91.2 | 94.2 | 101.2 | 91.2 |
| Total Liabilities | 391 | 392 | 437 | 431 |
| Cash-Flow Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PBT | 10 | 22 | 25 | 23 |
| OPBWC | 21 | 28 | 27 | 21 |
| Change in Receivables | 19 | -13 | 10 | -12 |
| Change in Inventories | 5 | -32 | -18 | 3 |
| Change in Payables | 22 | -10 | 21 | -18 |
| Other Changes | 4 | 4 | 8 | -7 |
| Working Capital Change | 50 | -51 | 21 | -34 |
| Cash Generated From Operations | 71 | -23 | 48 | -13 |
| Tax | -6 | -3 | -7 | 1 |
| Cash Flow From Operations | 65 | -26 | 41 | -12 |
| Purchase of PPE | -3.6 | -6 | -3 | -1.29 |
| Sale of PPE | 0.2 | 0.1 | 0.26 | 0.2 |
| Cash Flow From Investment | -2.5 | -7 | 2.5 | 5.8 |
| Borrowing | 0 | 0 | 0 | 0 |
| Dividend | 0 | 0 | 0 | 0 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | -1.5 | -1.6 | -1.6 | -0.8 |
| Cash Flow from Financing | -1.5 | -1.6 | -1.6 | -0.8 |
| Net Cash Generated | 61 | -34.6 | 41.9 | -7 |
| Cash at the Start | 71 | 132 | 97 | 139 |
| Cash at the End | 132 | 97.4 | 138.9 | 132 |
| Name | Designation | Experience | Linkedin Profile |
|---|---|---|---|
| Leo Joseph | MD | 25+ |
|
| David Brian Dyas | Director | 30+ |
|
| Vivek Gupta | CFO | 25+ |
|